Xtant Medical Holdings, Inc.

AMEX:XTNT

Medical - Devices

Healthcare
$0.36 -0.16%

-$0.00 today

Market cap
$50.37M
Beta
-0.17
P/E (TTM)
33.4
EPS (TTM)
$0.01
52W Low $0.40High $0.95

Volume 0.16M

Average 0.16M

XTNT Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Xtant Medical Holdings, Inc.AMEX: XTNT

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development declines year over year

Q1 FY2026 research & development of $435K fell 1.8% year over year, ahead of the -9.0% change in trailing-twelve-month research & development. Sequentially, it fell 5.2% from the prior quarter. Over 3 fiscal years it compounded at +31.9% a year.

Context

  • Research & development amounted to 1.6% of revenue in FY2025, down 0.5 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of -1.8% holds above the trailing-twelve-month pace of -9.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$435K-5.2% QoQ
Last fiscal yearDec 2025
$2.1M-11.9% YoY
LTMMar 2026
$2.09M-9.0% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-1.8%——
1 year-11.9%——
3-year CAGR+31.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
2.1M USD
Year-over-year change
-11.9%
4-year CAGR
+24.7%

Research & Development vs competitors

How XTNT compares with its peers on the latest reported figures

  • XTNT's LTM Mar 2026 research & development of $2.09M is the 7th highest of the 8 companies compared; the peer median is $5.46M.
  • Its year-over-year change of -9.0% is the 7th highest of 8, against a peer median of -5.9%.
  • Research & development amounts to 1.7% of revenue for XTNT, versus a peer median of 27.9%.
XTNT Competitors Peer median
Research & Development for XTNT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RCELAVITA Medical, Inc.LTM Mar 2026$20.18M -5.9%+14.6%27.9%
VANIVivani Medical, Inc.LTM Mar 2026$18.17M +11.9%+8.6%—
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$13.34M -7.2%+1.9%38.8%
LUCDLucid Diagnostics Inc.LTM Mar 2026$5.46M -7.8%+691.2%106.3%
EXOZeXoZymes, Inc.LTM Mar 2026$4.25M +96.3%+120.0%—
APYXApyx Medical CorporationLTM Mar 2026$3.33M -25.7%-9.5%6.0%
XTNTXtant Medical Holdings, Inc.LTM Mar 2026$2.09M -9.0%+31.9%1.7%
FONRFONAR CorporationLTM Mar 2026$1.77M +13.3%+1.8%1.7%
Peer median (excluding XTNT) $5.46M-5.9%+8.6%27.9%

Competitors are the stored peer set for XTNT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue55.26M57.97M91.3M117.27M133.93M
Cost of Revenue22.77M25.83M35.84M49.05M49.65M
Gross Profit32.49M32.14M55.47M68.22M84.27M
Gross Margin58.8%55.4%60.8%58.2%62.9%
Research & Development870K915K1.34M2.39M2.1M
Selling, General & Admin35.47M37.98M64.29M77.91M74.89M
Operating Expenses36.34M38.89M65.63M80.29M76.99M
Depreciation & Amortization1.34M1.3M3.17M4.22M5.22M
EBITDA(2.51M)(5.43M)5.08M(7.88M)15.9M
EBITDA Margin-4.5%-9.4%5.6%-6.7%11.9%
Operating Income(3.85M)(6.76M)(10.16M)(12.07M)7.28M
Operating Margin-7.0%-11.7%-11.1%-10.3%5.4%
Interest Income031K149K094K
Interest Expense995K1.69M2.94M4.16M3.67M
Other Income / Expenses(995K)(1.66M)9.12M(4.19M)(283K)
Income Before Tax(4.85M)(8.42M)(1.04M)(16.26M)7M
Pre-Tax Margin-8.8%-14.5%-1.1%-13.9%5.2%
Income Tax Expense069K(1.7M)187K2.03M
Net Income(4.85M)(8.49M)660K(16.45M)4.97M
Net Margin-8.8%-14.6%0.7%-14.0%3.7%
EPS (Basic)(0.06)(0.09)0.01(0.12)0.04
EPS (Diluted)(0.06)(0.09)0.01(0.12)0.03
Weighted Avg Shares85.46M94.09M119.09M133.67M139.53M
Weighted Avg Shares (Diluted)85.46M94.09M126.79M133.67M150.04M

Xtant Medical Holdings, Inc.

AMEX:XTNT

Intrinsic Alpha fair value

Locked

Current Price

$0.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.